Concurrence of dermatological and ophthalmological morbidity in onchocerciasis

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 106, Issue 4, 2012, Pages 243-251

  Coffeng, L E ^a   Fobi, G ^b   Ozoh, G ^c   Bissek, A C ^d   Nlatte B O ^e   Enyong, P ^f   Olinga Olinga, J M ^g   Zoure H G M ^b   Habbema, J D F ^a   Stolk, W A ^a   de Vlas, S J ^a   Boussinesq, M ^h   Noma, M ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b African Programme for Onchocerciasis Control   (Burkina Faso)

^c UNIVERSITY OF NIGERIA   (Nigeria)

^d UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^e Hopital Central de Yaounde   (Cameroon)

^f Tropical Medicine Research Station   (Cameroon)

^g WORLD HEALTH ORGANIZATION   (Switzerland)

^h INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

Burden of disease; Concurrence; Correlation; Eye disease; Onchocerciasis; Skin disease

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLINDNESS; CHILD; DEPIGMENTATION; DERMATOLOGY; DISEASE ASSOCIATION; ENDEMIC DISEASE; EXPOSURE; FEMALE; HUMAN; INFECTION; LIVER NODULE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; ONCHOCERCIASIS; OPHTHALMOLOGY; POPULATION; PREVALENCE; SCHOOL CHILD; SENSITIVITY ANALYSIS; SKIN DISEASE; SYMPTOM; VISUAL IMPAIRMENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANIMALS; ANTIPARASITIC AGENTS; CAMEROON; CHILD; COINFECTION; FEMALE; HUMANS; IVERMECTIN; MALE; MIDDLE AGED; ONCHOCERCA; ONCHOCERCIASIS; ONCHOCERCIASIS, OCULAR; PREVALENCE; QUALITY OF LIFE; SIMULIIDAE; YOUNG ADULT;

SOLANUM AETHIOPICUM;

EID: 84858294271     PISSN: 00359203     EISSN: 18783503     Source Type: Journal    
DOI: 10.1016/j.trstmh.2011.12.006     Document Type: Article

References (43)

1. Duke B.O. The population dynamics of Onchocerca volvulus in the human host. Trop Med Parasitol 1993, 44:61-68.
2. Enk C.D. Onchocerciasis-river blindness. Clin Dermatol 2006, 24:176-180.
3. Control APfO Year 2009 Progress Report 2009, World Health Organization, Geneva.
4. Browne S.G. Onchocercal depigmentation. Trans R Soc Trop Med Hyg 1960, 54:325-334.
5. Anderson J., Fuglsang H., Hamilton P.J.S., Marshall T.F.C. Studies on onchocerciasis in the United Cameroon Republic. I. Comparison of populations with and without Onchocerca volvulus. Trans R Soc Trop Med Hyg 1974, 68:190-208.
6. Anderson J., Fuglsang H., Hamilton P.J., de Marshall T.F. Studies on onchocerciasis in the United Cameroon Republic. II. Comparison of onchocerciasis in rain-forest and Sudan-savanna. Trans R Soc Trop Med Hyg 1974, 68:209-222.
7. McMahon J.E., Sowa S.I., Maude G.H., Kirkwood B.R. Onchocerciasis in Sierra Leone.2: A comparison of forest and savanna villages. Trans R Soc Trop Med Hyg 1988, 82:595-600.
8. Burnham G.M. Onchocerciasis in Malawi. 1. Prevalence, intensity and geographical distribution of Onchocerca volvulus infection in the Thyolo highlands. Trans R Soc Trop Med Hyg 1991, 85:493-496.
9. Little M.P., Basanez M.G., Breitling L.P., Boatin B.A., Alley E.S. Incidence of blindness during the onchocerciasis control programme in western Africa, 1971-2002. J Infect Dis 2004, 189:1932-1941.
10. Brattig N.W. Pathogenesis and host responses in human onchocerciasis: impact of Onchocerca filariae and Wolbachia endobacteria. Microbes Infect 2004, 6:113-128.
11. Rubio de Kromer M.T., Medina-De la Garza C.E., Brattig N.W. Differences in eosinophil and neutrophil chemotactic responses in sowda and generalized form of onchocerciasis. Acta Trop 1995, 60:21-33.
12. Ali M.M., Elghazali G., Montgomery S.M., et al. Fc gamma RIIa (CD32) polymorphism and onchocercal skin disease: implications for the development of severe reactive onchodermatitis (ROD). Am J Trop Med Hyg 2007, 77:1074-1078.
13. Brattig N.W., Tischendorf F.W., Reifegerste S., Albiez E.J., Berger J. Differences in the distribution of HLA antigens in localized and generalized form of onchocerciasis. Trop Med Parasitol 1986, 37:271-275.
14. Hoerauf A., Kruse S., Brattig N.W., Heinzmann A., Mueller-Myhsok B., Deichmann K.A. The variant Arg110Gln of human IL-13 is associated with an immunologically hyper-reactive form of onchocerciasis (sowda). Microbes Infect 2002, 4:37-42.
15. Meyer C.G., Gallin M., Erttmann K.D., et al. HLA-D alleles associated with generalized disease, localized disease, and putative immunity in Onchocerca volvulus infection. Proc Natl Acad Sci U S A 1994, 91:7515-7519.
16. Murdoch M.E., Payton A., Abiose A., et al. HLA-DQ alleles associate with cutaneous features of onchocerciasis. The Kaduna-London-Manchester Collaboration for Research on Onchocerciasis. Human immunol 1997, 55:46-52.
17. Murray C.J.L., Lopez A.D. Progress and directions in refining the global burden of disease approach: a response to Williams. Health Econ 2000, 9:69-82.
18. Mace J.M., Boussinesq M., Ngoumou P., Enyegue Oye J., Koeranga A., Godin C. Country-wide rapid epidemiological mapping of onchocerciasis (REMO) in Cameroon. Ann Trop Med Parasitol 1997, 91:379-391.
19. Enyong P., Traore S., Demanou M., et al. African Programme for Onchocerciasis Control (APOC): Onchocerca volvulus transmission by Simulium squamosum in two regions in the Republic of Cameroon [in French]. Bull Soc Pathol Exot 2006, 99:272-277.
20. Murdoch M.E., Hay R.J., Mackenzie C.D., Williams J.F., Ghalib H.W., Cousens S., et al. A clinical classification and grading system of the cutaneous changes in onchocerciasis. Br J Dermatol 1993, 129:260-269.
21. Ozoh G.A., Murdoch M.E., Bissek A.C., et al. The African Programme for Onchocerciasis Control: impact on onchocercal skin disease. Trop Med Int Health 2011, 16:875-883.
22. WHO Methods of assessment of avoidable blindness. WHO Offset Publication No 54 1980, World Health Organization, Geneva.
23. Babalola O.E., Maegga B., Katenga S., et al. APOC impact assessment studies: baseline ophthalmological findings in Morogoro, Tanzania. Afr J Med Med Sci 2008, 37:327-332.
24. Umeh R.E., Mahmoud A.O., Hagan M., et al. Prevalence and distribution of ocular onchocerciasis in three ecological zones in Nigeria. Afr J Med Med Sci 2010, 39:267-275.
25. Mathers C.D., Ezzati M., Lopez A.D. Measuring the burden of neglected tropical diseases: the global burden of disease framework. PLoS Negl Trop Dis 2007, 1:e114.
26. Andrews G., Sanderson K., Beard J. Burden of disease. Methods of calculating disability from mental disorder. Br J Psychiatry 1998, 173:123-131.
27. Mathers C.D., Iburg K.M., Begg S. Adjusting for dependent comorbidity in the calculation of healthy life expectancy. Popul Health Metr 2006, 4:4.
28. van Baal P.H., Hoeymans N., Hoogenveen R.T., de Wit G.A., Westert G.P. Disability weights for comorbidity and their influence on health-adjusted life expectancy. Popul Health Metr 2006, 4:1.
29. Murray C.J.L., Lopez A.D. The global burden of disease 1996, World Health Organization, Geneva.
30. Mathers C, Vos T, Stevenson C. The burden of disease and injury in Australia. Canberra: AIHW 1999. Document No.: AIHW cat. no. PHE 17.
31. McKechnie N.M., Braun G., Connor V., et al. Immunologic cross-reactivity in the pathogenesis of ocular onchocerciasis. Invest Ophthalmol Vis Sci 1993, 34:2888-2902.
32. McKechnie N.M., Gurr W., Yamada H., Copland D., Braun G. Antigenic mimicry: Onchocerca volvulus antigen-specific T cells and ocular inflammation. Invest Ophthalmol Vis Sci 2002, 43:411-418.
33. Makunde W.H., Salum F.M., Massaga J.J., Alilio M.S. Clinical and parasitological aspects of itching caused by onchocerciasis in Morogoro, Tanzania. Ann Trop Med Parasitol 2000, 94:793-799.
34. Murdoch M.E., Asuzu M.C., Hagan M., et al. Onchocerciasis: the clinical and epidemiological burden of skin disease in Africa. Ann Trop Med Parasitol 2002, 96:283-296.
35. Rees J., Murray C.S. Itching for progress. Clin experiment dermatol 2005, 30:471-473.
36. Gonzalez-Munoz M., Garate T., Puente S., Subirats M., Moneo I. Induction of histamine release in parasitized individuals by somatic and cuticular antigens from Onchocerca volvulus. Am J Trop Med Hyg 1999, 60:974-979.
37. Remme J.H.F. The global burden of onchocerciasis in 1990 2004, World Health Organization, Geneva.
38. Murdoch M.E. Onchodermatitis. Curr opinion infect dis 2010, 23:124-131.
39. WHO Onchocerciasis and its control 1995, World Health Organization, Geneva.
40. Alonso L.M., Murdoch M.E., Jofre-Bonet M. Psycho-social and economical evaluation of onchocerciasis: a literature review. Soc Med 2009, 4:8-31.
41. van der Werf M.J., de Vlas S.J., Brooker S., et al. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop 2003, 86:125-139.
42. Flanagan W., McIntosh C.N., Le Petit C., Berthelot J.M. Deriving utility scores for co-morbid conditions: a test of the multiplicative model for combining individual condition scores. Popul Health Metr 2006, 4:13.
43. Haagsma J.A., van Beeck E.F., Polinder S., Toet H., Panneman M., Bonsel G.J. The effect of comorbidity on health-related quality of life for injury patients in the first year following injury: comparison of three comorbidity adjustment approaches. Popul Health Metr 2011, 9:10.